PURPOSE:The application of quality of life tools for the sarcoidosis population has shown a variance between static objective tests used by physicians, and patient self assessment. The present challenges to the accurate perception and characterization of sarcoidosis disease severity call for the need to couple assessment tools that could provide a more comprehensive view of sarcoidosis expression. We set out to evaluate the correlation between common parameters of sarcoidosis expression and a published sarcoidosis severity scoring system.
METHODS:Sarcoidosis patients were recruited from a study evaluating immune expression and parameters of sarcoidosis severity. Demographics, CXR (by Scadding stage), spirometry(normal, restrictive, obstructive groups), Fatigue scores (grouped as Not Tired=10-21; Tired=22-34; Very Tired-35-50); Dypnea score (grouped as mild=1-4; moderate=5-8; severe=9-11) from this study were assessed to determine the correlation with a 2006 disease severity scoring system that used PFT and sarcoidosis organ involvement. Severity scores were grouped into low (<8), moderate (8 to <9) and high > 9). Data are expressed as the mean ± the standard deviation or as frequencies and proportions and the Chi Square test used for variable analysis.
RESULTS: Data were obtained for 21 patients, all African American, (M=8,F= 13), 48±7 yrs old at study entry. Organ involvement included lung (95%) skin, lymph nodes, eye (24% each). CXRs were in stages 0 or 1 (43%), or stage 2-4(57%). Spirometry was normal, restrictive, or obstructive in 29%, and mixed in 14% of the pts respectively. Mean severity score was 8.76 ± 1.0 with pts in the low (33%), moderate (29%), and high (38%) severity levels. Severity score did not show a significant correlation with fatigue or dyspnea scores, although there was a trend towards more moderate/severe CXRs within the high severity score group.
CONCLUSION: This racially homogeneous sarcoidosis patient cohort with a small variation in calculated severity score manifested a wide variation in scores reflecting disease symptomatology.
CLINICAL IMPLICATIONS: Ongoing investigations explaining how this disparity impacts treatment would help refine the overall management and outcome of patients.
DISCLOSURE: Gloria Westney, No Financial Disclosure Information; No Product/Research Disclosure Information